Hepatocyte growth factor can guide treatment of Mycoplasma pneumoniae pneumonia in children
| Autor: | Zhi Hua Wang, Hai Yun Yao, Lun Qin Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Mycoplasma pneumoniae medicine.disease_cause Azithromycin Gastroenterology 03 medical and health sciences 0302 clinical medicine Immunology and Microbiology (miscellaneous) Internal medicine medicine Predictive marker Oncogene biology business.industry C-reactive protein Bacterial pneumonia Articles General Medicine medicine.disease Molecular medicine 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Hepatocyte growth factor business medicine.drug |
| Zdroj: | Experimental and Therapeutic Medicine. |
| ISSN: | 1792-1015 1792-0981 |
| Popis: | The objective of the present study was to explore the role of hepatocyte growth factor (HGF) in directing treatment of Mycoplasma pneumoniae pneumonia (MP). Serum levels of HGF were assessed using ELISA in 65 pediatric patients with MP, 42 with bacterial pneumonia and 30 healthy controls. Serum levels of C-reactive protein (CRP), the standard guide for MP treatment, were also examined in severe and non-severe MP. The sensitivity and specificity of HGF and CRP in assessing the outcome of azithromycin treatment of MP were compared using receiver operating characteristic curves. HGF levels were elevated in MP and bacterial pneumonia patients compared with healthy controls. HGF levels were also significantly higher in severe MP than in non-severe MP. HGF showed higher sensitivity and specificity than CRP in assessing outcomes of azithromycin treatment of MP. The results of the present study indicated that HGF may be used to detect severe MP and to direct its management. Furthermore, HGF may be better predictive marker to assess the effectiveness of azithromycin treatment of MP than CRP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|